Results 201 to 210 of about 2,058,358 (352)

Identification of serum C4BPA as a potential diagnostic marker of right ventricular remodelling via proteomic analysis

open access: yesESC Heart Failure, EarlyView.
Abstract Aims Right ventricular (RV) remodelling, a progressive condition characterized by maladaptive cardiac structural and functional changes, primarily results from prolonged pressure overload in patients with pulmonary hypertension (PH). Accurate, universal and easy‐to‐use biomarkers for assessing the severity of RV remodelling are lacking.
Xuenan Wang   +5 more
wiley   +1 more source

Early administration of SGLT2 inhibitors in hospitalized patients: A practical guidance from the current evidence

open access: yesESC Heart Failure, EarlyView.
Abstract Sodium‐glucose cotransporter‐2 (SGLT2) inhibitors represent one of the main cornerstones of heart failure treatment. Nevertheless, while the cardiovascular beneficial effects of these drugs have been clearly demonstrated by several clinical trials, in clinical practice, it remains challenging to identify the appropriate timing to start SGLT2 ...
Ruggero Mazzotta   +10 more
wiley   +1 more source

Characteristics and Outcomes of Hospitalized Patients With Heart Failure and Reduced vs Preserved Ejection Fraction A Report From the Japanese Cardiac Registry of Heart Failure in Cardiology (JCARE-CARD)

open access: bronze, 2009
Miyuki Tsuchihashi‐Makaya   +9 more
openalex   +2 more sources

Dapagliflozin effect on functional mitral regurgitation and myocardial remodelling: The DEFORM trial

open access: yesESC Heart Failure, EarlyView.
Abstract Aims Functional mitral regurgitation (FMR) is associated with adverse outcomes in patients with heart failure, and current guideline‐directed medical therapy (GDMT) offers limited efficacy in managing FMR. This study aims to evaluate the therapeutic impact of the sodium‐glucose cotransporter 2 inhibitor (SGLT2i) dapagliflozin in patients with ...
Zhuoshan Huang   +18 more
wiley   +1 more source

Distinguishing heart failure with reduced ejection fraction from heart failure with preserved ejection fraction: A phenomics approach [PDF]

open access: yes
Aim: Pathophysiological differences between patients with heart failure with preserved (HFpEF) and reduced (HFrEF) ejection fraction (EF) remain unclear.
Chong, Jenny   +20 more
core  

Right ventricular strain predicts outcome in patients receiving sacubitril/valsartan: A sub‐analysis of DISCOVER‐ARNI

open access: yesESC Heart Failure, EarlyView.
Angiotensin receptor/Neprilysin inhibitors (ARNI) have shown to considerably improve the clinical outcome of patients with heart failure and reduced ejection fraction (HFrEF). Identifying individuals who may benefit from ARNI the most could markedly enhance patient management.
Maria Concetta Pastore   +15 more
wiley   +1 more source

Tai Chi in Patients With Heart Failure With Preserved Ejection Fraction [PDF]

open access: green, 2012
Gloria Y. Yeh   +7 more
openalex   +1 more source

Clinical characteristics and long‐term outcomes in patients with apical hypertrophic cardiomyopathy

open access: yesESC Heart Failure, EarlyView.
Abstract Aims As a special type of hypertrophic cardiomyopathy (HCM), apical HCM (ApHCM) has different clinical characteristics while its nature history and prognosis are not well recognized. We aimed to describe the characteristics and outcomes of ApHCM and identify predictors of adverse outcomes.
Meng Guo   +3 more
wiley   +1 more source

Home - About - Disclaimer - Privacy